H. pylori eradication should be surrogate in treatment of active/inactive duodenal ulcers -- Astra Merck.

HELICOBACTER PYLORI ERADICATION IN INACTIVE ULCERS SHOULD BE "SURROGATE" for prevention of duodenal ulcer relapse, Astra Merck Director of Gastrointestinal Clinical Research Garry Neil, MD, maintained at a Jan. 28 International Business Communications meeting on H. pylori in Washington, D.C. "We would suggest that cure of H. pylori infection can and should be regarded as a surrogate marker for prevention of duodenal ulcer disease irrespective of the presence of" an active crater "at the time of diagnosis," Neil said.